BioSpace News Archive

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Gemina Laboratories Ltd. is pleased to announce that it has qualified for trading on the OTCQB Venture Market in the United States operated by the OTC Markets Group Inc. and the Company’s common shares have commenced trading on the OTCQB under the symbol “GLABF.” The Company’s common shares will continue to trade on the CSE Exchange under the symbol “GLAB” and on the Frankfurt Exchange under the symbol “817".

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced the completion of its previously announced merger with AVROBIO, Inc.

Coya Therapeutics, Inc. announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age.

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

The Muscular Dystrophy Association celebrates the U.S. Food and Drug Administration’s expanded approval of ELEVIDYS.

Geron Corporation, a commercial stage biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Radiopharm Theranostics Limited, a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company, and its affiliates.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report - Endometrial cancer - Global Clinical Trial Landscape.